Building a medtech brand?
We run PR and public affairs for companies in this market: from category launches and funding announcements to NHS procurement and regulatory communications.
Genomics
Human genetics data science for drug discovery
Health data & AI platforms
Oxford-based data science company applying human genetics and polygenic risk scoring to drug discovery, insurance underwriting and precision health.
The read
Genomics (formerly branded Genomics plc) builds polygenic risk score technology that predicts individual genetic disease risk, sold into four buyer segments: insurance underwriting, employer workforce health, life-sciences drug discovery and healthcare-provider precision health.
Its selection as PRS provider for Our Future Health, a programme aiming to become the UK's largest health research cohort, is one of its most independently significant UK deployments, alongside its 2024 Series C that brought in new life-sciences-focused investors.
The Bridgehead view
Genomics' four-segment sales model, the same underlying risk-scoring technology sold into insurance, employers, pharma and providers, is a more diversified revenue base than most single-buyer health-data vendors in this index, worth noting when comparing resilience across the category.
Work with us
Working across the healthcare sector?
We advise NHS-facing organisations, providers and health systems on reputation, policy engagement and communications that understand the sector.
The firm that knows medtech
We map this sector because
we represent it.
Whether you build medical technology or run the health systems that buy it, we know the market, the media and the regulatory landscape it operates in. Thirty minutes with a partner tells you if we can help.
